Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential
Yuan Yu,1–3 Jialu Li,1–3 Xuejun Zhu,4 Xiaowen Tang,2,5 Yangyi Bao,6 Xiang Sun,6 Yuhui Huang,1,2 Fang Tian,4 Xiaomei Liu,1,2 Lin Yang1–3 1The Cyrus Tang Hematology Center, 2Collaborative Innovation Center of Hematology, Soochow University, 3Suzhou Cancer Immunotherapy a...
Guardado en:
Autores principales: | Yu Y, Li J, Zhu X, Tang X, Bao Y, Sun X, Huang Y, Tian F, Liu X, Yang L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a6114d62af91421bb95cf6e914ba97b0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
STAGE-DEPENDENT IMMUNOPATHOGENETIC FEATURES OF ACUTE NONLYMPHOBLASTIC AND ACUTE LYMPHOBLASTIC LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014) -
A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity
por: Maristella Maggi, et al.
Publicado: (2021) -
Profound leukemia cutis in a patient with relapsed T-cell acute lymphoblastic leukemia
por: Ambika Nohria, BA, et al.
Publicado: (2021) -
DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study
por: Hamid Hashemi Yeganeh, et al.
Publicado: (2021) -
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz MJ, et al.
Publicado: (2020)